The Fulham Shore Share Discussion Threads

[garth] 19/10/2007 12:23

Well ansc, I don't think you'll be waiting that long. They seem to be working in the right direction and the price looks like it might just be starting to react. Results should help to raise the profile again.

G.

[ansc] 18/10/2007 09:56

I honestly haven't a clue, G, it's like trying to read tea leaves in the bottom of a cup! My optimism has simply been based on Quadramed's future prospects which, when added to the FD's two purchases of late, the recently announced Japanese contract and the eventual (hopefully) turnround at Unicus has tempted me to raise my stake.

But you know me, 'egg-on-face' is a distinct possibility. After all, it took five years for our beloved CAR to come good so I've possibly got a mere two-and-a-half years to while away with FUL!

[garth] 18/10/2007 09:20

Ansc,

What are your expectations of results?

G.

[a.fewbob] 17/10/2007 22:45

Do RNS releases incur a cost? Seems a bit harsh!

[ansc] 17/10/2007 20:18

150k buy recorded after hours. Pleasing to see that I'm not on my own with a little optimism as regards FUL's prospects.

The directors must be expecting that the recent Japanese contract win will make a significant difference to future earnings otherwise they could quite justifiably have not bothered with the expense of a RNS last week but waited until the results announcement in a couple of weeks instead....just a thought.

[ansc] 14/10/2007 11:10

First chance I've had to study Thursday's announcement in detail and found the following sentence quite intriguing: "In conjunction with other contracts already secured, this contract will mean that at current capacity, Fulcrum's Japanese subsidiary has a virtually full order book for the next two years."

Taking a simplistic view that the £2.5m contract fees is spread evenly over each of the next four years (i.e. roughly £600k per annum) means that last years £1.8m turnover by origin in Japan will increase by at least 33% with just this single contract. Furthermore (again simplistically), if one can assume that the Japanese subsidiary's costs - presumably staff and accommodation - will not need to increase dramatically, a large chunk of each year's £600k could, or even should, end up on FUL's bottom line.

On reflection, even the recent disappointing Unicus announcement might have a silver lining. If management have learnt lessons from the 2006 Quadramed acquisition - where the maximum earn-out ended up being paid - then it's obviously in their best interests to keep Unicus' earnings (during the earn-out year to 31 March 2008) as low as possible .... by fair means or foul!

Overall, I'm still happy to go along with the FD's feeling of optimism. If the next set of figures in 3-4 weeks time includes a favourable chairman's statement, even the market may be forced to sit-up and take notice; it most certainly didn't last Thursday.

[scruff1] 13/10/2007 07:19

Ironic that we still finish lower than last week.

[boadicea] 11/10/2007 09:47

Is this the Jap prospect they were talking about a year or so ago or a different one out of the blue?

[garth] 11/10/2007 09:32

What an overwhelming response to the news that the Japanese unit is at capacity for the next 2 years. And that on the back of the interim statement that the US operation was seeing an improvement as forecast...?

[scruff1] 11/10/2007 07:36

Yep. Got to agree with garth - spot on. Well done.

[garth] 11/10/2007 07:26

Good timing Ansc :0)

[blackfox] 11/10/2007 07:10

Fulcrum Pharma PLC
11 October 2007




FULCRUM PHARMA PLC
('the Group' or 'the Company')


Fulcrum wins contract to execute a phase III clinical oncology project in Japan

Fulcrum Pharma plc (AIM: FUL), the drug development and regulatory services
company is pleased to announce that its Japanese subsidiary has won a contract
to execute a phase III clinical oncology development study in Japan on behalf of
a major Pharma company. The project runs from September 2007 for four years and
is worth over 600 million JPY (over £2.5 million) in fees. In conjunction with
other contracts already secured, this contract will mean that at current
capacity, Fulcrum's Japanese subsidiary has a virtually full order book for the
next two years.

Fulcrum has established itself in Japan as a specialist oncology clinical
research organization where it now conducts studies for a range of Japanese
companies, global pharma and Japanese government funded academic groups.

Alastair Devlin, Director of Japanese Strategy of Fulcrum Pharma, said: 'We are
delighted to win this contract with a major Pharma company which has recognised
our strength in oncology. Cancer is the leading cause of death in Japan which is
the world's largest oncology market.'

For further information, please contact:

Fulcrum Pharma PLC
Jon Court, Chief Executive Tel: [phone]

Seymour Pierce
Jonathan Wright Tel: [phone]

About Fulcrum Pharma plc

Fulcrum Pharma plc is a drug development and regulatory services business that
provides global expertise to achieve drug development and regulatory approval
milestones.

Fulcrum Pharma offers immediate access to a highly credible, integrated
development team that provides strategic and operational leadership required to
ensure that new drugs move smoothly from discovery research to product approval

Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange



This information is provided by RNS
The company news service from the London Stock Exchange

[scruff1] 09/10/2007 20:08

Directors of VOG bought in last year at 95p. Now 25p!!??

[ansc] 09/10/2007 09:21

In view of the FD's two purchases of late - the last one being just before the start of FUL's 'close' period - and the share price droop yesterday, popped in and bought a few more this morning. After all, if the FD of a company doesn't know the current state-of-play, what chance has any of us mere shareholders got!

[ansc] 03/10/2007 14:32

I somehow missed this announcement when it came out, not that it made any difference to the sp:-

FULCRUM PHARMA PLC ("the Group" or "the Company")

Fulcrum and LORENZ in strategic alliance to develop and deliver "Creative eRegulatory SolutionsTM"

Fulcrum Pharma plc (AIM: FUL), the drug development and regulatory services
company is pleased to announce the intent to form a strategic alliance with
LORENZ Life Sciences Group.

Fulcrum is committed to developing new products and services which enable Pharma
and Biotech companies to achieve faster regulatory approval of new medicines.
LORENZ develops and markets software solutions for the life sciences industry
that are mainly geared towards submission assembly, review, publishing,
validation and management for regulated environments. LORENZ and Fulcrum believe
that tailored IT solutions are critically important for ensuring the quality of
pharmaceutical regulatory submissions and, if designed and applied
appropriately, can have a dramatic impact on the time to regulatory submission
and approval.

As a first step in the strategic alliance, the two companies have agreed to
establish a joint sales and marketing campaign in North America and Europe to
provide tailored e-publishing solutions in this growing market. The joint
product offering will combine the strategic regulatory and e-publishing skills
of Fulcrum with the submission management software solutions developed by
LORENZ. Together, the two companies will offer Creative eRegulatory SolutionsTM
in a cost-effective and tailored approach to new and existing clients.

Jon Court, Chief Executive of Fulcrum Pharma, said: "Together we will be well
positioned to meet the increasing demand for regulatory services which comprise
an e-publishing component. The alliance with LORENZ will increase our capacity
to deliver e-products to our clients and enhance the reach of our regulatory
business. We look forward to this exciting partnership and the development of a
series of new regulatory products and services"

Wolfgang Witzel, President of Lorenz, said. "This partnership provides a
tailored solution to meet our customers' needs, combining the regulatory skills
in Fulcrum with the e-publishing expertise in LORENZ. Working with Fulcrum will
enable us to enhance our regulatory product offering in a way that directly
benefits our clients. This is an exciting opportunity for both LORENZ and
Fulcrum"

[platts] 14/9/2007 11:08

the purchase of shares by the finance director of a company is always particularly bullish for the obvious reason. this is a slow burn but I am optimistic.

[ansc] 03/9/2007 21:26

He's managed to do it yet again:

'FULCRUM PHARMA PLC ("the Company")

Director Shareholding

The Company was informed today that Geoffrey Smith, Finance Director, has bought
200,000 ordinary shares in the Company at an average price of 3.5p per share.

As a result, Mr Smith now holds 3,232,744 ordinary shares, representing
approximately 1.8% per cent of the current issued share capital of the Company.'

I find it surprising that those whom were happy to take shares in the March placing @ 4.25p/per share - for the acquisition of Unicus - are not diving in with the price currently now at an apparent knock-down price of 3.75p. Mr Smith, and as FD he should know better than anyone, clearly sees a bargain!

[ansc] 21/8/2007 08:32

Same thought crossed my mind last night. I've been looking to add on 'weak' trading days and the offer price didn't get anywhere near 3.25p last week and certainly not yesterday.

One trading rule for directors but another different one for investors apparently!

[ansc] 20/8/2007 21:11

But he does actually hold three million which should help make him, particularly as FD, concentrate on the job in hand!

[dak] 20/8/2007 19:59

Had he bought a million it might have been worth noting but £3K is hardly a big deal!!!!!

[ansc] 20/8/2007 16:51

Every little helps:

" FULCRUM PHARMA ("the Company")

Director Shareholding

The Company was informed today that Geoffrey Smith, Finance Director, has bought
100,000 ordinary shares in the Company at a price of 3.25p per share.

As a result, Mr Smith now holds 3,032,744 ordinary shares, representing
approximately 1.7% per cent of the current issued share capital of the Company."